J0715 — Injection, ceftizoxime sodium, per 500 mg
J0715 is a HCPCS Level II code for injection, ceftizoxime sodium, per 500 mg. It belongs to the Drugs Administered Other Than Oral Method section. It was terminated on December 31, 2025 and is not valid on new claims.
This code has been terminated
CMS terminated J0715 on December 31, 2025. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for J0715
- Long descriptor
- Injection, ceftizoxime sodium, per 500 mg
- Short descriptor
- Ceftizoxime sodium / 500 mg
- Added
- January 1, 1995
- Terminated
- December 31, 2025
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J0715
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J0715 is not quite right, the correct code is very often within a few positions of it.
- J0701Injection, cefepime hydrochloride (baxter), not therapeutically equivalent to maxipime, 500 mg
- J0702Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg
- J0703Injection, cefepime hydrochloride (b braun), not therapeutically equivalent to maxipime, 500 mg
- J0706Injection, caffeine citrate, 5 mg
- J0710Injection, cephapirin sodium, up to 1 gmterminated
- J0712Injection, ceftaroline fosamil, 10 mg
- J0713Injection, ceftazidime, per 500 mg
- J0714Injection, ceftazidime and avibactam, 0.5 g/0.125 g
- J0716Injection, centruroides immune f(ab)2, up to 120 milligrams
- J0717Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
- J0720Injection, chloramphenicol sodium succinate, up to 1 gm
- J0725Injection, chorionic gonadotropin, per 1,000 usp units
- J0735Injection, clonidine hydrochloride, 1 mg
- J0736Injection, clindamycin phosphate, 300 mg
- J0737Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg
- J0738Injection, lenacapavir, 1 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)
Questions about J0715
What is HCPCS code J0715?
J0715 is a HCPCS Level II code for injection, ceftizoxime sodium, per 500 mg. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J0715?
The CMS HCPCS file marks J0715 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is J0715 still valid?
No. J0715 was terminated on December 31, 2025 and should not be used on new claims.